Ads MeAgain runs on Meta (Facebook / Instagram) and the App Store. Open a Meta card to see the ad copy and why it likely works.
Meta (Facebook / Instagram)
Active ads
~530#6 of 43 apps on Onbo Hub
FewerMore (up to ~6,000)
As of Oct 23, 2026 · Meta Ad Library · This is the number of ads, not ad spend.
Ad Strategy
Mostly partnership ads under the names of creators who are on GLP-1s themselves. They open with a struggle nobody explains, like how to get through the day after a shot, then show the shot-day checklist and the medication level chart. The copy is a long first-person story.
Long-running ads
Running 30+ days. The longer an ad runs, the more likely it works.
Apple Ads (App Store)
Countries where ads ran (EU)
5 countriesof 25 in the EU
- DE
- ES
- FR
- IE
- IT
Last shown Oct 12, 2026 · 10 ad records in the last 90 days (counted per country and format)
How the ad looks
MeAgain: GLP-1 Tracker App
Wegovy Pill Zepbound GLP1 Shot
Ad
Apple only publishes ads shown in the EU, so US and Japan ads, keywords and spend aren't included. Source: Apple Ad Repository
MeAgain
Est. Max Revenue$77,000/mo
Onboarding Steps27
Meta Ads~530 active
Apple Ads5 EU countries
A tracking app for the trending weight loss drug GLP-1. While its approach differs from AI calorie tracking apps, both are rooted in the fundamental human desire to lose weight and improve appearance.
UX Highlights
What stands out is that a screen appears first to reassure users about data privacy. For apps like this, protecting user privacy is essential, and it's important to first give users peace of mind.
Monetization
Offers two options — an annual plan (MOST POPULAR, 75% OFF) or a monthly plan — and pushes the annual plan. There is no mention of a free trial. The top of the paywall displays social proof such as "#1 GLP-1 Companion App" and "370K+ users," along with reviews, to build trust.
You May Also Like
Popular apps in Health & Fitness
